

IMPLEMENTATION OF REGULATORY GUIDANCE FOR JAK INHIBITORS USE IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES: RESULTS FROM AN INTERNATIONAL APPROPRIATENESS STUDY

FEBRUARY 7th, 2024 | h. 4:30 pm CET

JAKi represent an emerging and resourceful class of drugs to treat many immune-mediated inflammatory diseases. The EMA PRAC decision was emanated, mainly based on the results of the ORAL surveillance study to raise caution regarding the use of JAKi in specific categories of patients that were considered at high risk. However, there is still uncertainty regarding how to translate this warning into clinical practice. The main focus of this webinar is to summarize the results of this international appropriateness study that aimed to implement recommendations from regulatory guidance.



Silvio Danese
Director, Gastroenterology and Endoscopy
IRCCS Ospedale San Raffaele, Milan, Italy
Professor of Gastroenterology
University Vita-Salute San Raffaele, Milan, Italy



Laurent Peyrin-Biroulet
Full Professor of Medicine IBD Unit
Department of Gastroenterology Nancy
University Hospital, France



Virginia Solitano
University Vita-Salute San Raffaele, Milan, Italy
University of Western Ontario, London, Ontario, Canada



Paola Facheris
U.O. Dermatology, IRCCS Humanitas,
Rozzano, Milan, Italy



Magnus Petersen
Parker Institute, Copenhagen University Hospital,
Bispebjerg and Frederiksberg, Denmark

Welcome and Intro of meeting objectives 5'

Silvio Danese, *Italy*

Laurent Peyrin-Biroulet, *France*

The appropriateness study and results from gastroenterology 15'

Virginia Solitano, *Italy*

Results from dermatology 10'

Paola Facheris, *Italy*

Results from rheumatology 10'

Magnus Petersen, *Denmark*

Q&A 10'

[CLICK HERE TO REGISTER](#)

This program has been supported by an independent grant from Galápagos and Pfizer, Inc

ibdscope.com



ORGANIZATION OFFICE
Materia Prima srl
www.materia1a.it
segreteria@materia1a.it